Industry
Biotechnology
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Loading...
Open
10.67
Mkt cap
3B
Volume
6.1M
High
10.71
P/E Ratio
-5.93
52-wk high
18.33
Low
9.99
Div yield
N/A
52-wk low
3.76
Portfolio Pulse from Benzinga Insights
March 19, 2024 | 5:35 pm
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 2:26 pm
Portfolio Pulse from Benzinga Insights
March 13, 2024 | 4:16 pm
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 4:55 pm
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 2:44 pm
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 1:53 pm
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 11:35 am
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 8:56 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.